Latest update on how the Interim Cancer Drug Fund will be implemented at your local Strategic Health Authority level.

The next Government has the power to invest in the future of cancer care. We need every parliamentary candidate to make a firm commitment to cancer support, and you can make this happen.

Read NICE’s press release, as well as a further article in PharmaTimes

NICE states that azacitidine is not recommended as a treatment option for people with intermediate-2 or high risk myelodysplastic syndromes (MDS)

Prime minister’s office responds to the AML (Acute Myeloid Leukaemia) petition for azacitidine

NICE to lose powers to decide on new drugs.

“Scientists at King’s have developed a vaccine treatment for Leukaemia that can be used to stop the disease returning after chemotherapy or bone marrow transplant. The vaccine is due to be tested on patients for the first time. Eventually it is hoped the drug, which activates the body's own immune system against the leukaemia, could be used to treat other types of cancers. ” KCL website.

This CML (Chronic Myeloid Leukaemia) patient is facing similar issues as our MDS patients with azacitidine, as NICE’s preliminary decision is NOT TO recommend 2 drugs that can treat this […]

A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.